A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
This new technology could one day significantly expand the market for gene-editing biotechs.
Overview
An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic material, it's being informally called the "DNA shredder."
For shareholders of CRISPR Therapeutics (NASDAQ: CRSP) and its gene-editing peers like Intellia Therapeutics (NASDAQ: NTLA) and Beam Therapeutics (NASDAQ: BEAM), the emergence of a new form of genetic medicine could have major financial implications down the road. Let's unpack what the new tech can do and what it means for CRISPR Therapeutics as well as these other stocks.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.